Literature DB >> 19008531

Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo.

William R Lagor1, Robert J Brown, Sue-Anne Toh, John S Millar, Ilia V Fuki, Margarita de la Llera-Moya, Tiffany Yuen, George Rothblat, Jeffrey T Billheimer, Daniel J Rader.   

Abstract

OBJECTIVE: Apolipoprotein F (ApoF) is a protein component of several lipoprotein classes including HDL. It is also known as lipid transfer inhibitor protein (LTIP) based on its ability to inhibit lipid transfer between lipoproteins ex vivo. We sought to investigate the role of ApoF in HDL metabolism. METHODS AND
RESULTS: Adeno-associated viruses (AAV) based on serotype 8, were used to overexpress either murine or human ApoF in mice. Overexpression of murine ApoF significantly reduced total cholesterol levels by 28% (P<0.001), HDL by 27% (P<0.001), and phospholipid levels by 19% (P<0.001). Overexpression of human ApoF had similar effects. Human ApoF was nearly exclusively HDL-associated in mice. In agreement with this finding, greater than 90% of the ApoF in human plasma was found on HDL(3), with only a small amount on LDL. Overexpression of mouse ApoF accelerated the plasma clearance of [(3)H]-cholesteryl ether labeled HDL. Plasma from mice overexpressing ApoF showed improved macrophage cholesterol efflux on a per HDL-C basis.
CONCLUSIONS: ApoF overexpression reduces HDL cholesterol levels in mice by increasing clearance of HDL-CE. ApoF may be an important determinant of HDL metabolism and reverse cholesterol transport.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008531      PMCID: PMC2766561          DOI: 10.1161/ATVBAHA.108.177105

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

1.  Lipid transfer inhibitor protein activity deficiency in normolipidemic uremic patients on continuous ambulatory peritoneal dialysis.

Authors:  A P Serdyuk; R E Morton
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-09       Impact factor: 8.311

2.  Isolation and partial characterization of a new acidic apolipoprotein (apolipoprotein F) from high density lipoproteins of human plasma.

Authors:  S O Olofsson; W J McConathy; P Alaupovic
Journal:  Biochemistry       Date:  1978-03-21       Impact factor: 3.162

3.  Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I.

Authors:  U J Tietge; C Maugeais; W Cain; D Grass; J M Glick; F C de Beer; D J Rader
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

4.  Inhibition of lipid transfer by a unique high density lipoprotein subclass containing an inhibitor protein.

Authors:  T Nishide; J H Tollefson; J J Albers
Journal:  J Lipid Res       Date:  1989-02       Impact factor: 5.922

5.  Markedly elevated lipid transfer inhibitor protein in hypercholesterolemic subjects is mitigated by plasma triglyceride levels.

Authors:  R E Morton; V Nunes; L Izem; E Quintão
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

6.  Purification and characterization of human plasma proteins that inhibit lipid transfer activities.

Authors:  Y S Son; D B Zilversmit
Journal:  Biochim Biophys Acta       Date:  1984-10-04

7.  Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F.

Authors:  X Wang; D M Driscoll; R E Morton
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

8.  Purification and molecular cloning of human apolipoprotein F.

Authors:  J R Day; J J Albers; T L Gilbert; T E Whitmore; W J McConathy; G Wolfbauer
Journal:  Biochem Biophys Res Commun       Date:  1994-09-15       Impact factor: 3.575

9.  Isolation and characterization of simple and complex lipoproteins containing apolipoprotein F from human plasma.

Authors:  E Koren; W J McConathy; P Alaupovic
Journal:  Biochemistry       Date:  1982-10-12       Impact factor: 3.162

10.  Regulation of lipid transfer between lipoproteins by an endogenous plasma protein: selective inhibition among lipoprotein classes.

Authors:  R E Morton; D J Greene
Journal:  J Lipid Res       Date:  1994-05       Impact factor: 5.922

View more
  24 in total

1.  Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition.

Authors:  Richard E Morton; Diane J Greene
Journal:  J Lipid Res       Date:  2011-09-21       Impact factor: 5.922

2.  Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism.

Authors:  Yan Liu; Richard E Morton
Journal:  Curr Opin Lipidol       Date:  2020-08       Impact factor: 4.776

3.  Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo.

Authors:  Tomoyuki Yasuda; Didier Grillot; Jeffery T Billheimer; François Briand; Philippe Delerive; Stephane Huet; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-28       Impact factor: 8.311

4.  ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters.

Authors:  Richard E Morton; Yan Liu; Lahoucine Izem
Journal:  J Lipid Res       Date:  2019-09-11       Impact factor: 5.922

5.  Common Variants in 6 Lipid-Related Genes Discovered by High-Resolution DNA Melting Analysis and Their Association with Plasma Lipids.

Authors:  John F Carlquist; Jason T McKinney; Benjamin D Horne; Nicola J Camp; Lisa Cannon-Albright; Joseph B Muhlestein; Paul Hopkins; Jessica L Clarke; Chrissa P Mower; James J Park; Zachary P Nicholas; John A Huntinghouse; Jeffrey L Anderson
Journal:  J Clin Exp Cardiolog       Date:  2011-07-10

6.  Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

Authors:  William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader
Journal:  Atherosclerosis       Date:  2014-01-10       Impact factor: 5.162

7.  Structure-function relationships of HDL in diabetes and coronary heart disease.

Authors:  Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein
Journal:  JCI Insight       Date:  2020-01-16

8.  Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.

Authors:  Thomas A Bell; Mark J Graham; Richard G Lee; Adam E Mullick; Wuxia Fu; Dan Norris; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2013-06-25       Impact factor: 5.922

9.  Lactase persistence and lipid pathway selection in the Maasai.

Authors:  Kshitij Wagh; Aatish Bhatia; Gabriela Alexe; Anupama Reddy; Vijay Ravikumar; Michael Seiler; Michael Boemo; Ming Yao; Lee Cronk; Asad Naqvi; Shridar Ganesan; Arnold J Levine; Gyan Bhanot
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism.

Authors:  Xian-Cheng Jiang; Weijun Jin; Mahmood M Hussain
Journal:  Nutr Metab (Lond)       Date:  2012-08-16       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.